181 related articles for article (PubMed ID: 35547096)
1. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Caputo V; De Falco V; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Martini G; Corte CMD; Ciardiello D; Poliero L; De Vita F; Orditura M; Fasano M; Franco R; Caraglia M; Avitabile A; Scalamogna R; Marchi B; Ciardiello F; Troiani T; Napolitano S
Ther Adv Med Oncol; 2022; 14():17588359221096878. PubMed ID: 35547096
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
3. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
5. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
6. Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.
Popa AM; Stejeroiu MA; Iaciu C; Olaru M; Orlov Slavu C; Parosanu A; Stanciu IM; Pirlog C; Pavel S; Nitipir C
Cureus; 2023 Dec; 15(12):e50709. PubMed ID: 38111812
[TBL] [Abstract][Full Text] [Related]
7. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.
De Falco V; Poliero L; Vitello PP; Ciardiello D; Vitale P; Zanaletti N; Giunta EF; Terminiello M; Caputo V; Carlino F; Di Liello R; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Orditura M; De Vita F; Fasano M; Napolitano S; Martini G; Della Corte CM; Franco R; Altucci L; Ciardiello F; Troiani T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32234730
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.
Teuwen LA; Roets E; D'Hoore P; Pauwels P; Prenen H
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175010
[TBL] [Abstract][Full Text] [Related]
10. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
11. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
12. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
13. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
14. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
15. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.
Deak KL; Jackson JB; Valkenburg KC; Keefer LA; Robinson Gerding KM; Angiuoli SV; Datto MB; McCall SJ
J Mol Diagn; 2021 Oct; 23(10):1324-1333. PubMed ID: 34314880
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy.
Yoshii Y; Okazaki S; Takeda M
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440540
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Pinet S; Durand S; Perani A; Darnaud L; Amadjikpe F; Yon M; Darbas T; Vergnenegre A; Egenod T; Simonneau Y; Le Brun-Ly V; Pestre J; Venat L; Thuillier F; Chaunavel A; Duchesne M; Fermeaux V; Guyot A; Lacorre S; Bessette B; Lalloué F; Durand K; Deluche E
Front Oncol; 2023; 13():1104659. PubMed ID: 36923436
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
Blanc-Durand F; Camilleri GM; Bayle A; Aldea M; Vasseur D; Ouali K; Michels J; Pautier P; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Ponce-Aix S; Italiano A; Leary A
Cancer; 2024 Jun; ():. PubMed ID: 38824658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
